Narjust Florez, MD

Narjust Florez, MD, is the associate medical director of the Cancer Care Access Program and a thoracic medical oncologist at the Dana-Farber Cancer Institute in Boston, Massachusetts.

Articles

Reviewing Key Data in Resectable and ROS1+ NSCLC With Drs Florez and Sabari

September 9th 2025

Narjust Florez, MD, and Joshua K. Sabari, MD, sit down with Chandler Park, MD, FACP, to discuss the latest abstracts in lung cancer presented during the International Association for the Study of Lung Cancer 2025 World Conference on Lung Cancer.

Dr Florez on the Significance of a Consensus Manuscript From the BTG Lung Cancer Conference

September 4th 2025

Narjust Florez, MD, discusses the publication of a consensus manuscript in Cancer on recommendations for clinical strategies for lung cancer management.

Dr Florez on Emerging Strategies to Address Checkpoint Inhibitor Resistance in NSCLC

August 8th 2025

Narjust Florez, MD, discusses emerging strategies to address immune checkpoint inhibitor resistance in non–small cell lung cancer.

Dr Florez on the Role of First-Line IO for BRAF V600E+ Metastatic NSCLC

August 8th 2025

Narjust Florez, MD, discusses current treatment preferences in frontline IO for BRAF V600E–mutated metastatic non–small cell lung cancer.

Dr Florez on the Role of Chemoimmunotherapy in Borderline Resectable NSCLC

August 8th 2025

Narjust Florez, MD, discusses treatment preferences in borderline resectable NSCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Dr Florez on First-Line Treatment Factors in EGFR+ NSCLC

August 7th 2025

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the Bridging the Gaps in Lung Cancer 2025 meeting.

Dr Florez Highlights Real-Time Polling Results on Treatment Preferences in SCLC

August 7th 2025

Narjust Florez, MD, discusses current treatment preferences in SCLC, based on real-time polling conducted during the 2025 Bridging the Gaps in Lung Cancer meeting.

Dr Florez on the Importance of Establishing Consensus Within the Evolving Lung Cancer Treatment Landscape

July 30th 2025

Narjust Florez, MD discusses the importance of establishing expert consensus in the evolving lung cancer treatment landscape in 2025.

Florez Focuses on Patient-Centered NSCLC Biomarker Testing Discussions

September 5th 2024

Dr Florez discusses ways that she helps patients with lung cancer understand the importance of biomarker testing.

Dr Florez on Addressing Key Gaps in Lung Cancer Care

August 5th 2024

Narjust Florez, MD, discusses the importance of addressing crucial gaps in care for patients with lung cancer.